308 related articles for article (PubMed ID: 36678880)
1. Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.
Muralidhar A; Potluri HK; Jaiswal T; McNeel DG
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678880
[TBL] [Abstract][Full Text] [Related]
2. Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices.
Deshayes E; Fersing C; Thibault C; Roumiguie M; Pourquier P; Houédé N
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370743
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
5. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
6. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
7. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
[TBL] [Abstract][Full Text] [Related]
8. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Marshall CH; Antonarakis ES
Cancer Treat Res Commun; 2020 Jan; 23():100164. PubMed ID: 31978677
[TBL] [Abstract][Full Text] [Related]
10. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
14. Advances in
Ling SW; de Blois E; Hooijman E; van der Veldt A; Brabander T
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297601
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeted alpha therapy for prostate cancer.
De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
[TBL] [Abstract][Full Text] [Related]
16. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Liu X; Fang GC; Lu H; Shi ZD; Chen ZS; Han CH
Drugs Today (Barc); 2023 Jan; 59(1):37-49. PubMed ID: 36811416
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival outcomes of salvage [
Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
[TBL] [Abstract][Full Text] [Related]
20. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]